Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223298 · ClinicalTrials.gov registry record · Phase 3
Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
NCT03223298 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 75 participants.
The verdict
NCT03223298, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study aims to determine whether the injection of botulinum toxin A or placebo (unpreserved 0.9% sodium chloride) into the masseter and temporalis muscles provides pain relief and improved jaw function in those who suffer from myofascial pain disorder. The study hypothesis is that botulinum toxin A injection is superior to placebo. The specific research questions are: 1. Is the injection of botulinum toxin A superior to placebo for the improvement in pain? 2. Is the injection of botulinum toxin A superior to placebo for the improvement in function or quality of life (QOL)? 3. Are there any adverse effects that result from injection of botulinum toxin A or placebo into the masseters and temporalis muscles? Limited data exists to support the use of botulinum toxin A in the management of myofascial pain disorder of the masticatory region. Botulinum toxin A is not FDA approved for intra-muscular injection within the masticatory region. Its use in the masticatory region is considered off-label but performed without significant known complications. This study will provide the opportunity to quantitate and qualitate any complications in a large prospective sample of patients.
Interventions
- DRUG Botulinum toxin type A
- DRUG 0.9% Sodium Chloride Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2018-08-31 |
| Est. Completion | 2020-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03223298
The ClinicalTrials.gov registry entry for NCT03223298 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botulinum toxin type A is the first listed.
NCT03223298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03223298 about?
NCT03223298 is a clinical study titled "Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles". This study aims to determine whether the injection of botulinum toxin A or placebo (unpreserved 0.9% sodium chloride) into the masseter and temporalis muscles provides pain relief and improved jaw function in those who suffer from myofascial pain disorder. The study hypothesis is that botulinum toxi...
What is the current status of trial NCT03223298?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2018-08-31. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT03223298?
The interventions under investigation include: Botulinum toxin type A (DRUG), 0.9% Sodium Chloride Injection (DRUG).
Who is sponsoring clinical trial NCT03223298?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.